Dr. Hugo Morales Briceno interviews Prof. David Devos from the University of Lille, France, about the results of the phase 1/2 clinical trial using intracerebroventricular anaerobic dopamine in Parkinson’s disease with L-dopa-related complications.

<a href="https://pubmed.ncbi.nlm.nih.gov/39775041/">Read the article.</a>

Dr. Hugo Morales Briceno interviews Prof. David Devos from the University of Lille, France, about the results of the phase 1/2 clinical trial using intracerebroventricular anaerobic dopamine in Parkinson’s disease with L-dopa-related complications. Read the article.

Dr. Hugo Morales Briceno interviews Prof. David Devos from the University of Lille, France, about the results of the phase 1/2 clinical trial using intracerebroventricular anaerobic dopamine in Parkinson’s disease with L-dopa-related complications.

<a href="https://pubmed.ncbi.nlm.nih.gov/39775041/" rel="noopener noreferrer">Read the article.</a>

Intraventricular infusion of anaerobic dopamine

Stay up to date on novel, clinically-relevant research findings in Parkinson's disease and other movement disorders. Each episode of the International Parkinson and Movement Disorder Society podcast discusses a relevant development in the field, including highlighted journal articles and interviews with the authors.

Share Intraventricular infusion of anaerobic dopamine

Sign up to save your podcasts

Intraventricular infusion of anaerobic dopamine

Intraventricular infusion of anaerobic dopamine